Enrico Borrelli
Enrico Borrelli is an expert in Ophthalmology at IRCCS Ospedale San Raffaele (Italy). As of October 2026, ScienceLeadR ranks Enrico Borrelli in the top 1% of experts worldwide for Retinal Diseases. Enrico Borrelli has authored 371 publications, the most recent in 2026, and is an investigator in 2 clinical trials, 1 of them ongoing. SLR score: 1,185 (community average: 125). How the SLR is computed.
LeadR Profile
Ophthalmology
Subspecialties: Surgery - Medical Imaging - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2023 - 2026
Number : 371
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Clinical exit strategy in anti-VEGF therapy for neovascular AMD: incidence of recurrence and risk factors for relapse. PMID 42850327 — eye, macular degeneration, vascular endothelial growth factor a, incidence, tears, ophthalmology, biomarkers, retinal pigments, retinal pigment epithelium, tomography, optical coherence, risk factors, therapeutics, retinaldehyde, subretinal fluid, epithelium | Graefes Arch Clin Exp Ophthalmol | 2026 | 0 |
| Deep learning-based prediction of one-year functional and structural outcomes in treatment-naïve DMO after anti-VEGF therapy. PMID 42844343 — vascular endothelial growth factor a, retina, deep learning, tomography, optical coherence, therapeutics, learning | Eye (Lond) | 2026 | 0 |
| En face visualization of the outer choroidal vessels in regions with geographic atrophy. PMID 42839113 — eye, macular degeneration, atrophy, ophthalmology, retinaldehyde, wounds and injuries, geographic atrophy | Graefes Arch Clin Exp Ophthalmol | 2026 | 0 |
| Differential Remodeling of the Macular Neovascular Network under Different Anti-VEGF Agents in Age-Related Macular Degeneration. PMID 42774544 — eye, macular degeneration, vascular endothelial growth factor a, angiography, ranibizumab, angiopoietins, therapeutics, angiopoietin-2 | Ophthalmol Sci | 2026 | 0 |
| The Behavior of the External Limiting Membrane and Ellipsoid Zone in Diabetic Macular Edema: A Population AI-Assisted Optical Coherence Tomography Study. PMID 42765790 — eye, ophthalmology, tomography, biomarkers, macular edema, visual acuity, tomography, optical coherence, artificial intelligence, retinaldehyde, membranes, edema | Invest Ophthalmol Vis Sci | 2026 | 0 |
Clinical Studies 2
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Photobiomodulation in Dry Age Related Macular Degeneration NCT06046118 — eye, macular degeneration, masks, signs and symptoms, therapeutics | N/A | Recruiting | 2023 |
LeadR Networks
Main global connection map